Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 5/20 | 0.40 |
| ▸ | HRH1 | P35367 | 5/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | ACR | P10323 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28761846 | 0.85 | BCHE (0.41) | MAPTALDH1A1 | |
| SCHEMBL2964166 | 0.81 | BRD4 (0.40) | ALDH1A1 | |
| SCHEMBL10317771 | 0.79 | S1PR3 (0.37) | MAPTALDH1A1 | |
| SCHEMBL11022255 | 0.79 | MEN1 (0.44) | MAPTALDH1A1 | |
| SCHEMBL10598218 | 0.78 | SNCA (0.39) | MAPTALDH1A1 | |
| SCHEMBL9773406 | 0.78 | CA12 (0.43) | — | |
| SCHEMBL8927990 | 0.77 | GAA (0.42) | MAPTALDH1A1 | |
| SCHEMBL9364127 | 0.77 | HTT (0.43) | CACNA1BPPARA | |
| SCHEMBL6259776 | 0.76 | S1PR3 (0.36) | MAPTALDH1A1 | |
| SCHEMBL10596213 | 0.75 | ALDH1A1 (0.41) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928225-B2 | Oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2011-04-19 | — | — | US | disclosed |
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ASTRAZENECA AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222335-A1 | Process For The Preparation Of N,N'-Disubstituted Oxabispidines | ADH1C, ADH5, ADH1A | MAPT 4288/4885ALDH1A1 114/4885CACNA1H 1110/4885 |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | MAPT 4680/4885ALDH1A1 1142/4885CACNA1H 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.